Primary biliary cholangitis affects an estimated 30,000 to 50,000 people in the United States, with women making up about 75 to 80 percent of cases.

Sclerosing cholangitis involves inflammation of bile ducts, either within the liver or outside the liver. Thus, the flow of bile from the liver to the intestine may be obstructed.

Acute cholangitis is diagnosed on the basis of the clinical features, supported by laboratory evidence of systemic infection. Imaging is helpful in revealing biliary obstruction and any underlying ...

Secondary sclerosing cholangitis is a chronic cholestatic biliary disease, which unlike primary sclerosing cholangitis, is thought to develop as a consequence of known injuries. The presence of ...

Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease of uncertain etiology characterized by the destruction of the intrahepatic and extrahepatic bile ducts through ...

Source: Adobe Stock. Ahn and colleagues identified 194 adult patients with acute cholangitis (AC) and 260 with alcohol-associated hepatitis (AH) who were admitted to Mayo Clinic between 2010 and 2019.

Primary sclerosing cholangitis is progressive, and there is no known therapy to prevent cirrhosis, liver transplant, or progression to cancer, but a new investigation suggests statins might help.

SAN DIEGO — Quantitative magnetic resonance cholangiopancreatography may help assess changes in the biliary tree and aid monitoring of patients with primary sclerosing cholangitis, according to ...

The European Commission (EC) has conditionally approved Ipsen’s Iqirvo (elafibranor) for the treatment of primary biliary cholangitis (PBC), becoming the first drug approved for the liver ...

NEWARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic ...